Neoadjuvant Hormone Therapy Prior to Prostate Surgery Shows Potential to Reduce Cancer Relapse

For decades, the standard treatment for high-risk prostate cancer has primarily relied on radical prostatectomy followed by monitoring for recurrence, a process often marked by anxiety over rising PSA levels and the subsequent need for aggressive secondary therapies. However, a significant paradigm shift in oncology is emerging, centered on the use of neoadjuvant hormone therapy administered before surgery. Recent clinical research indicates that this preemptive approach may successfully shrink tumors and fundamentally alter the post-surgical trajectory for patients. By integrating hormone therapy into the pre-surgical phase, clinicians aim to reduce the persistence of malignant cells, thereby decreasing the likelihood of cancer recurrence. This tactical change offers a promising alternative to the traditional surgery-first protocol, potentially leading to more durable remission rates for high-risk patients. As data continues to support this methodology, it signals a potential evolution in standard urological care, shifting the focus from reactive follow-up to proactive, preemptive intervention to improve long-term survival outcomes and minimize the need for subsequent radiation or chemotherapy.